Stay updated on KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial page.

Latest updates to the KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial page
- Check5 days agoChange DetectedResults have been posted for the study, including primary and secondary outcomes (PFS, response rate, and overall survival) and related time frames. Updated study dates reflect the start date, primary completion date, and study completion date.SummaryDifference0.4%

- Check12 days agoNo Change Detected
- Check34 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference3%

- Check41 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.1%

- Check55 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing the old v3.0.1, and the 'Back to Top' link has been removed.SummaryDifference0.2%

- Check62 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.2%

- Check70 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, as well as updates to related medical topics. However, several important drug information and genetic resources have been removed.SummaryDifference2%

Stay in the know with updates to KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial page.